Here's why the EMvision (ASX:EMV) share price is up 9% this week

The EMVision share price is up by almost 10% this week, after the company announced a cash injection and a new chief scientific officer.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EMVision Medical Devices Ltd (ASX: EMV) share price has had a bumper week so far. Shares in the medical imaging company are up by 1.94% today, on the back of a week of gains. At the time of writing, the EMVision share price is up by 9.7% since the opening bell on Monday morning.

A week of good news for EMVision

EMVision's gains this week come after the company announced on Monday that it had received a $1.28 million cash refund for the financial year ending 30 June 2020. The incentive was paid to EMVision in relation to its research and development (R&D) work.

This brings EMVision's cash reserves to $13.1 million. Cash balance is of particular interest when looking at companies involved in R&D, where there are often gaps of time in between project developments.

On Thursday morning, EMVision announced the appointment of Professor Stuart Crozier as Chief Scientific Officer, noting that he is "globally recognised for his breakthroughs in Magnetic Resonance Imaging (MRI)".

Professor Crozier will now lead R&D efforts of EMVision's novel imaging products.

So what exactly does EMVision do?

Some Fools might recall us going into detail about what EMVision gets up to back in October. The company website states that EMVision "is developing a portable brain scanner for rapid, point of care, Stroke Diagnosis and Monitoring".

If that sounds complicated, it's probably because it is! Put simply, EMVision is working toward a solution that will support people suffering from a stroke, on-site. The company is currently developing a portable brain scanner that could save significant time diagnosing a stroke, therefore potentially lessening the impact of the stroke itself. 

According to a clinical trial result the company announced back in October, "It was observed that the EMVision device was able to classify stroke type (haemorrhagic or ischaemic) with an overall accuracy of between 93.3% and 96%."

More on the EMVision share price

EMVision shares have had an impressive 12 months. Year-over-year, the share price has rocketed over 300%. During its December 2018 IPO, EMVision's price was 25 cents a share. Lately, EMVision shares are trading in the $3 range, sitting at $3.16 at the time of writing.

With a market cap of around $213 million, EMVision certainly isn't the biggest player on the field, but it seems to be garnering plenty of attention since joining the game. 

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Business man marking buy on board and underlining it.
Broker Notes

6 ASX All Ords shares elevated to strong buy status after March sell-off

The ASX All Ords fell 8% in March after the US and Israel attacked Iran and oil and gas prices…

Read more »

Red buy button on an Apple keyboard with a finger on it.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Frustrated stock trader screaming while looking at mobile phone, symbolising a falling share price.
Share Market News

Why Beetaloo, Fortescue, Orora, and Whitehaven Coal shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man in a business suit leaps off a boulder in front of a blue sky.
Share Gainers

3 ASX 200 stocks surging 13% to 36% in this shortened trading week

Investors sent these three ASX 200 stocks flying higher following the Easter break. But why?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Amaero, Mesoblast, Telix, and Tivan shares are charging higher today

These shares are ending the week on a high. But why?

Read more »

A young couple stands next to a real estate agent in an empty apartment they are inspecting.
Real Estate Shares

Mirvac shares sink to their lowest level since 2015. Is this ASX property giant back on the radar?

Multi-year lows put Mirvac shares back on investors’ watchlists today.

Read more »

surprised child reading all about asx 200 shares in a newspaper
Share Market News

Why Magellan, Telix and Fortescue shares are grabbing headlines on Friday

Telix, Magellan, and Fortescue shares are catching ASX investor interest today. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
52-Week Lows

Harvey Norman just hit a 52-week low. Is this beaten-down ASX retailer becoming too cheap to ignore?

Harvey Norman sinks to 52-week low as sentiment weakens further.

Read more »